{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06116032",
            "orgStudyIdInfo": {
                "id": "Study02001227"
            },
            "organization": {
                "fullName": "Dartmouth-Hitchcock Medical Center",
                "class": "OTHER"
            },
            "briefTitle": "Immune Profiling for Cancer Immunotherapy Response",
            "officialTitle": "Immune Profiling for Cancer Immunotherapy Response",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "immune-profiling-for-cancer-immunotherapy-response"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-11",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-10-03",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-01-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-01-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-10-30",
            "studyFirstSubmitQcDate": "2023-10-30",
            "studyFirstPostDateStruct": {
                "date": "2023-11-03",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-11-06",
            "lastUpdatePostDateStruct": {
                "date": "2023-11-08",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Brock C. Christensen",
                "investigatorTitle": "Associate Professor of Epidemiology, Molecular and Systems Biology, and of Community and Family Medicine",
                "investigatorAffiliation": "Dartmouth-Hitchcock Medical Center"
            },
            "leadSponsor": {
                "name": "Dartmouth-Hitchcock Medical Center",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": true
        },
        "descriptionModule": {
            "briefSummary": "In patients clinically treated with FDA-approved immunotherapy the investigators will assess the predictive value of pre- and on-treatment 1) immune-methylation profiling across cancer types, and 2) immune-methylation profiling and cytokine profiling within cancer types."
        },
        "conditionsModule": {
            "conditions": [
                "Cancer",
                "Tumor, Solid",
                "Hematologic Malignancy",
                "Blood Cancer"
            ],
            "keywords": [
                "Immunotherapy"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": false,
            "designInfo": {
                "observationalModel": "COHORT",
                "timePerspective": "PROSPECTIVE"
            },
            "bioSpec": {
                "retention": "SAMPLES_WITH_DNA",
                "description": "Peripheral blood and FFPE tumor tissue"
            },
            "enrollmentInfo": {
                "count": 1500,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Standard of Care Checkpoint",
                    "description": "Patients receiving standard of care FDA approved immunotherapy",
                    "interventionNames": [
                        "Diagnostic Test: Methylation Cytometry"
                    ]
                },
                {
                    "label": "Bone Marrow Transplant",
                    "description": "Patients undergoing transplant for hematologic malignancy",
                    "interventionNames": [
                        "Diagnostic Test: Methylation Cytometry"
                    ]
                },
                {
                    "label": "CAR T",
                    "description": "Patients undergoing CAR T therapy",
                    "interventionNames": [
                        "Diagnostic Test: Methylation Cytometry"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DIAGNOSTIC_TEST",
                    "name": "Methylation Cytometry",
                    "description": "Assessment of the ability of Methylation Cytometry in pre-treatment peripheral blood and in repeated measures over the duration of treatment to predict treatment response or occurrence of adverse events.",
                    "armGroupLabels": [
                        "Bone Marrow Transplant",
                        "CAR T",
                        "Standard of Care Checkpoint"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Response to therapy",
                    "description": "The investigators will employ iRECIST, and outcome criteria will be clinically evaluated and include the primary endpoints of progression (non-responders) or response, with patients followed up every month for 6 months (or until death, loss to follow-up, or withdrawal of consent), judged according to the objective response rate (ORR) assessed using iRECIST.",
                    "timeFrame": "5 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Cancer patients receiving or will receive immunotherapy under FDA- approved indication (e.g. checkpoint inhibitor therapy with pembrolizumab, nivolumab, or ipilimumab, or cellular immunotherapy).\n* Participants are eligible regardless of the type of prior therapy (i.e. prior immunotherapy treated participants can be included).\n\nExclusion Criteria:\n\n* Pregnant women/fetuses/neonates\n* Prisoners\n* Decision-impaired individuals",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ],
            "studyPopulation": "Cancer patients who will receive or who are receiving immunotherapy under FDA- approved indication",
            "samplingMethod": "PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Brock C Christensen, PhD",
                    "role": "CONTACT",
                    "phone": "603-650-1827",
                    "email": "brock.c.christensen@dartmouth.edu"
                },
                {
                    "name": "Hannah G Stolrow, BA",
                    "role": "CONTACT",
                    "phone": "7205174950",
                    "email": "hannah.stolrow@dartmouth.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Brock C Christensen, PhD",
                    "affiliation": "Dartmouth College",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Dartmouth-Hitchcock Medical Center",
                    "status": "RECRUITING",
                    "city": "Lebanon",
                    "state": "New Hampshire",
                    "zip": "03756",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Hannah G Stolrow, BA",
                            "role": "CONTACT",
                            "phone": "720-517-4950",
                            "email": "hannah.stolrow@dartmouth.edu"
                        },
                        {
                            "name": "Brock C Christensen, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.64229,
                        "lon": -72.25176
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "35140201",
                    "type": "BACKGROUND",
                    "citation": "Salas LA, Zhang Z, Koestler DC, Butler RA, Hansen HM, Molinaro AM, Wiencke JK, Kelsey KT, Christensen BC. Enhanced cell deconvolution of peripheral blood using DNA methylation for high-resolution immune profiling. Nat Commun. 2022 Feb 9;13(1):761. doi: 10.1038/s41467-021-27864-7."
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "UNDECIDED"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000019337",
                    "term": "Hematologic Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M21314",
                    "name": "Hematologic Neoplasms",
                    "asFound": "Hematologic Malignancies",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M2853",
                    "name": "Immunomodulating Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}